{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T18:57:22Z","timestamp":1783277842791,"version":"3.54.6"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.humpath.2020.10.007","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T22:40:04Z","timestamp":1604443204000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["ESR1 genetic alterations and their association with clinicopathologic characteristics in advanced breast cancer: a single academic institution experience"],"prefix":"10.1016","volume":"107","author":[{"given":"C. Eric","family":"Freitag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-3828","authenticated-orcid":false,"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil V.","family":"Parwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-1696","authenticated-orcid":false,"given":"Zaibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2020.10.007_bib1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations - a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.humpath.2020.10.007_bib2","first-page":"284036","article-title":"Sex hormone receptor repertoire in breast cancer","volume":"2013","author":"Higa","year":"2013","journal-title":"Int J Breast Canc"},{"key":"10.1016\/j.humpath.2020.10.007_bib3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.mce.2014.11.015","article-title":"Estrogen receptors in breast carcinogenesis and endocrine therapy","volume":"418","author":"Huang","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.humpath.2020.10.007_bib4","doi-asserted-by":"crossref","first-page":"36863","DOI":"10.1074\/jbc.R100047200","article-title":"Nuclear receptor minireview series","volume":"276","author":"Olefsky","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2020.10.007_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.10.007_bib6","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod Pathol : Off J US Canad Acad Pathol Inc."},{"key":"10.1016\/j.humpath.2020.10.007_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.humpath.2020.10.007_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11912-013-0358-9","article-title":"The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?","volume":"16","author":"Johnston","year":"2014","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.humpath.2020.10.007_bib9","first-page":"75","article-title":"Extending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of action","volume":"14","author":"Gl\u00fcck","year":"2014","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.humpath.2020.10.007_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/GCO.0000000000000039","article-title":"The renaissance of endocrine therapy in breast cancer","volume":"26","author":"Williams","year":"2014","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.humpath.2020.10.007_bib11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.humpath.2020.10.007_bib12","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2020.10.007_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/2159-8290.CD-15-1523","article-title":"Activating ESR1 mutations differentially affect the efficacy of ER antagonists","volume":"7","author":"Toy","year":"2017","journal-title":"Canc Discov"},{"key":"10.1016\/j.humpath.2020.10.007_bib14","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.humpath.2020.10.007_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41379-018-0116-5","article-title":"Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing","volume":"32","author":"Ross","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.10.007_bib16","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1002\/cncr.32345","article-title":"ESR1 mutations in breast cancer","volume":"125","author":"Dustin","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2020.10.007_bib17","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2020.10.007_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.humpath.2020.05.005","article-title":"Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations","volume":"102","author":"Freitag","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2020.10.007_bib19","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2020.10.007_bib20","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen-receptor-a: a novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Canc Res"},{"key":"10.1016\/j.humpath.2020.10.007_bib21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.tranon.2017.07.004","article-title":"Comparison of ESR1 mutation in tumor tissue and matched plasma samples from metastatic breast cancer patients","volume":"10","author":"Takeshita","year":"2017","journal-title":"Transl Oncol"},{"key":"10.1016\/j.humpath.2020.10.007_bib22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13045-018-0670-9","article-title":"Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)","volume":"11","author":"Liang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.humpath.2020.10.007_bib23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/ng2006","article-title":"Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer","volume":"39","author":"Holst","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2020.10.007_bib24","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1349-7006.2009.01145.x","article-title":"Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients","volume":"100","author":"Tomita","year":"2009","journal-title":"Canc Sci"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720302136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720302136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:38:00Z","timestamp":1758645480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817720302136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":24,"alternative-id":["S0046817720302136"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2020.10.007","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESR1 genetic alterations and their association with clinicopathologic characteristics in advanced breast cancer: a single academic institution experience","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2020.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}